Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.
Dennis A EichenauerIna BühnenAnnette PlütschowCarsten KobeMarkus DietleinClemens-Martin WendtnerSven ThorspeckenMax S ToppMareike MauserBastian von TresckowMichael FuchsPeter BorchmannAndreas EngertPublished in: Hematological oncology (2022)